Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13509408 | 1.00 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL13051895 | 1.00 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL13248788 | 1.00 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL13509392 | 1.00 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL10222016 | 0.96 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL10221923 | 0.96 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL10222000 | 0.96 | ADRB3 (0.44) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL2158582 | 0.94 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL3062667 | 0.94 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13787423 | 0.94 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100028300-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100028300-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| US-7642235-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-7642235-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028300-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | CTRL, RPP30, RNASE1 | ADRB3 4315/4885ADRA2B 4456/4885ADRA2C 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.